Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
Hartung HP, Berger T, Bermel RA, Brochet B, Carroll WM, Holmøy T, Karabudak R, Killestein J, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Vollmer T, Buffels R, Garas M, Kadner K, Manfrini M, Wang Q, Freedman MS. Hartung HP, et al. Among authors: killestein j. J Neurol. 2024 Apr 22. doi: 10.1007/s00415-024-12326-z. Online ahead of print. J Neurol. 2024. PMID: 38649522
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. Hartung HP, et al. Among authors: killestein j. J Neurol. 2007 Jul;254(7):827-37. doi: 10.1007/s00415-006-0486-3. Epub 2007 Apr 24. J Neurol. 2007. PMID: 17457510 Review.
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Polman CH, et al. Among authors: killestein j. Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4. Lancet Neurol. 2010. PMID: 20610349
Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.
Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M; SOLAR study group. Smolders J, et al. Among authors: killestein j. J Neurol Sci. 2011 Dec 15;311(1-2):44-9. doi: 10.1016/j.jns.2011.04.013. Epub 2011 May 28. J Neurol Sci. 2011. PMID: 21620416 Clinical Trial.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
gMS-Classifier1 does not predict disability progression in multiple sclerosis.
van Rossum JA, Killestein J, Villar LM, Riskind PN, Freedman MS, Teunissen C. van Rossum JA, et al. Among authors: killestein j. Mult Scler. 2019 Jun;25(7):1010-1011. doi: 10.1177/1352458518798048. Epub 2018 Aug 31. Mult Scler. 2019. PMID: 30168749 Free PMC article. No abstract available.
309 results